Notice Regarding Registration of Investigator-Initiated Clinical Trial (jRCT) for "Nanvuranlat" in Biliary Tract Cancer
NQ Score
82/100
N1 Content Completeness
90
Key facts
- Notice Regarding Registration of Investigator-Initiated Clinical Trial (jRCT) for "Nanvuranlat" in Biliary Tract Cancer
- J-Pharma Co., Ltd. announced that an investigator-initiated clinical trial evaluating the combination of the LAT1 inhibitor "nanvuranlat" and immune checkpoint inhibitors for biliary tract cancer has been registered on jRCT.
- Source: PR TIMES
- Date: Tue May 19 2026 00:34:58 GMT+0900 (Japan Standard Time)
Direct answer
J-Pharma Co., Ltd. announced that an investigator-initiated clinical trial evaluating the combination of the LAT1 inhibitor "nanvuranlat" and immune checkpoint inhibitors for biliary tract cancer has been registered on jRCT.
- Citation
- Notice Regarding Registration of Investigator-Initiated Clinical Trial (jRCT) for "Nanvuranlat" in Biliary Tract Cancer (Tue May 19 2026 00:34:58 GMT+0900 (Japan Standard Time)), PR TIMES
- Source
- PR TIMES
- Date
- Tue May 19 2026 00:34:58 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
J-Pharma Co., Ltd. announced that an investigator-initiated clinical trial evaluating the combination of the LAT1 inhibitor "nanvuranlat" and immune checkpoint inhibitors for biliary tract cancer has been registered on jRCT.
AI Analysis
Frequently Asked Questions
- Q: Where is the clinical trial for nanvuranlat taking place?
- A: It is being conducted in Japan, with the Cancer Institute Hospital of JFCR as the representative facility.
- Q: What disease is targeted in this clinical trial?
- A: It targets the first-line treatment (maintenance therapy) of biliary tract cancer.
- Q: When did nanvuranlat receive Orphan Drug Designation from the FDA?
- A: It received the designation from the U.S. FDA in April 2022.